Please wait
Healthcare · Medical Devices · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
$195B
2.3%
36.40
Current price
$112.50
+0.0% todayUpdated 46 min ago
Open
$111.60
Previous close
$112.47
Day range
$111.11 – $112.75
Volume
N/A
36.4x P/E
Awaiting filing
2.3% yield
65/100 measured
Moderate liquidity
Recent price movement, key market context and the latest company information.
The latest saved price history for ABT, with its range and direction at a glance.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Investors usually follow ABT for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is bullish because fundamentals are solid at 70/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
$6.25B
TTM (2026-07-07)
ROE
10.6%
Return on equity
ROA
5.3%
Return on assets
Debt / equity
0.65
Lower is usually safer.
P/B ratio
3.81
Useful for book value support.
Dividend yield
2.3%
Current income signal.
85/100
Direction
Range-bound
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Trading liquidity looks supportive for the forecast to transmit into price action.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
$116.33
Analyst view
Buy
Analyst target
$120.20
Forecast refresh
Updated 5h ago
Quality score
69
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
$0.59
2025-01-15
Payment: TBA | Qualification: 2025-01-15 | Yield at declaration: N/A
$0.55
2024-10-15
Payment: TBA | Qualification: 2024-10-15 | Yield at declaration: N/A
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+6.4% across the latest saved price window.
Volatility
Low
Beta is 0.58. Price has historically moved more calmly than the wider market.
52-week position
55% of range
Price is sitting around the middle of its 52-week range.
Volume confirmation
N/A
Comparable volume data is not available.
high_energy_costs
ABT may also move because the HEALTHCARE sector may move with high_energy_costs. Confidence 63%.
PMG-MAN stated the pharmaceutical sector spends a large share of revenue on energy, reducing competitiveness industry-wide.
q1_2026_gdp_growth
ABT may also move because the HEALTHCARE sector may move with q1_2026_gdp_growth. Confidence 63%.
NBS data cited in the article shows the healthcare sector grew by 1.99% in Q1 2026 (vs 1.76% in Q1 2025), indicating sector-level growth dynamics affecting listed healthcare firms.
policy_stability_and_support
ABT may also move because the HEALTHCARE sector may benefit from policy_stability_and_support. Confidence 60%.
The sector would benefit from extended Presidential Executive Order, dedicated energy tariffs, and policies encouraging local API production to attract investment and boost local manufacturing.
local manufacturing / import substitution
ABT may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
ABT may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
ABT may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
ABT may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
ABT may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
ABT
Abbott Laboratories
Price: $112.50
P/E: 36.39806
Yield: 2.3%
ABBV
AbbVie Inc.
Price: $255.52
P/E: 72.994286
Yield: 2.7%
ALGN
Align Technology, Inc.
Price: $157.61
P/E: 27.310226
Yield: 0.0%
AMGN
Amgen Inc.
Price: $432.46
P/E: 26.875078
Yield: 2.3%
Industry
Medical Devices
Employees
122000
Exchange
NYQ
Ticker
ABT
